biliary atresia

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

News

A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.